The Innovative Medicines Initiative (IMI2) –
Europe's largest public-private initiative
The Innovative Medicines Initiative (IMI) is an initiative aiming to make the European Union’s pharmaceutical research facilities more competitive. Competing industrial and research companies are working together to speed up the development of better and safer medicines as well as new therapeutic approaches for patients. The initiative was part of the EU’s Seventh Framework Programme for Research (FP7) and is being continued as IMI2 within the Horizon2020 programme since 2014. The overall budget for IMI2 is 3.276 billion Euros over a term of 10 years.
concentris also manages IMI projects and has ample experience (see our current IMI projects).
Sources and more information: